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RÉSUMÉ EN FRANCAIS 
Introduction: Le pseudoxanthome élastique (PXE) est une maladie génétique. Les mutations 
responsables ont été localisées au niveau du gène codant le transporteur transmembranaire 
ABC-C6. Des calcifications pathologiques des fibres élastiques de la peau, des yeux et du 
système cardiovasculaire en sont la conséquence. 
Buts: Evaluer les critères diagnostiques actuels du PXE en se basant sur les données 
moléculaires. 
Méthodes: 142 sujets provenant de 10 familles avec une anamnèse familiale positive 
pour le PXE ont été investiguées sur le plan clinique, histopathologique et génétique. 
Résultats: 25 sujets se sont avérés être homozygotes pour le gène PXE muté. 23 
d'entre eux ont présenté les manifestations cliniques et histopathologique typiques. Les 
deux autres souffraient d'une élastose et d'une dégénérescence maculaire si importante 
qu'un diagnostic de PXE ne pouvait pas être confirmé cliniquement. 67 sujets se sont 
révélés être des porteurs hétérozygotes et 50 ne présentaient pas de mutation. De ces 
117 sujets, 116 n'ont montré aucune lésion cutanée ou ophtalmique pouvant 
correspondre au PXE. Un seul des sujets sans mutation a présenté une importante 
élastose solaire ainsi qu'une cicatrisation de la rétine, imitant les lésions typiques du PXE. 
Quatre des 67 sujets hétérozygotes ont eu une biopsie de peau, dont les analyses 
histopathologique se sont avérées normales. 
Conclusion: Dans notre cohorte de patients, le PXE était transmis exclusivement de 
façon autosomique récessive. La corrélation retrouvée entre le génotype et le phénotype 
a permis de confirmer les critères diagnostiques majeurs actuels. Le diagnostic clinique 
peut être difficile, voir impossible, chez des patients atteints d'une élastose solaire 
importante et/ou d'une dégénérescence maculaire étendue. Dans ces cas, un test 
moléculaire est nécessaire afin de confirmer le diagnostic de PXE. A notre connaissance, 
notre étude présentée ici est le premier travail comparant des données cliniques à des 
données moléculaires dans le domaine du PXE. 
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ABSTRACT 
Background: Pseudoxanthoma elasticum (PXE) is a genetic disorder due to mutations in the 
gene encoding the transmembrane transporter protein adenosine triphosphate binding 
cassette (ABC)-C6, resulting in calcifications of elastic fibers in the skin, eyes and 
cardiovascular system. 
Objectives: To evaluate the diagnostic criteria for PXE based on molecular data. 
Methods: Of 10 families with a positive history of PXE 142 subjects were investigated for 
clinical symptoms, histological findings and genetic haplotype analysis. 
Results: Of these, 25 subjects were haplotypic homozygous for PXE and 23 had typical 
clinical and histopathological manifestations. Two of the 25 patients showed such marked 
solar elastosis and macular degeneration that PXE could not be confirmed clinically. 
Sixty-seven subject were haplotypic heterozygous carriers and 50 haplotypic 
homozygous unaffected. Of these 117 subjects, 116 showed no cutaneous or 
ophthalmologic signs of PXE. In one of the 50 haplotypic homozygous unaffected patients 
important solar elastosis and scaring of the retina mimicked PXE lesions. Only four of the 
67 haplotypic heterozygous carriers had biopsies of nonlesional skin; ail were 
histopathologically normal. 
Conclusions: In our patients, PXE presents as an autosomal recessive genodermatosis. 
Correlation of haplotype and phenotype confirmed actual major diagnostic criteria. In 
patients with marked solar elastosis and/ or severe macular degeneration clinical 
diagnosis can be impossible and molecular testing is needed to confirm the presence of 
PXE. To the best of our knowledge our large study compares for the first time clinical 
findings with molecular data. 
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BACKGROUND 
PXE is an inherited connective tissue disorder resulting in abnormal calcification of the 
elastic tissue network of the skin, eyes and cardiovascular system. The molecular defect 
was identified in the gene encoding the transmembrane transporter protein adenosine 
triphosphate binding cassette (ABC)-C6 1-7 chromosome 16p13.1. 1' 8 This gene encodes a 
transmembrane transporter protein which belongs to the same family of proteins as 
those defective in cystic fibrosis or Tangier disease. ABC-C6 is expressed primarily in the 
liver and the kidney, 9 suggesting that transporter dysfunction may lead to accumulation 
of an unknown substrate in the blood causing secondary dystrophie changes of elastic 
tissues. 10 
Skin lesions consist of yellowish papules or plaques with loss of dermal elasticity.11' 12 
Commonly affected sites are the flexures and periumbilical skin. 10 Mucous membrane 
involvement is not rare. 13 Skin lesions are usually noted in the second or third decade. 10 
Histology of skin lesions shows calcification, alteration and fragmentation of elastic 
structures in the mid dermis. 14 
Ocular involvement is characterized by angioid streaks, 15 breaks in the Bruch's 
membrane, with secondary changes of the retinal pigmented epithelium (peau d'orange), 
and choriocapillaris. 16 While the angioid streaks are asymptomatic at first, they become 
the sites of choroidal neovascularization and subretinal haemorrhages later in life and 
central loss of vision may occurs in the case of macular involvement. Cardiovascular 
manifestations usually develop last, and result from slowly progressive calcification of 
elastic arterial walls. 17 Reduction of vessel lumen causes ischemia, and excessive fragility 
of the vessel wall, is responsible for haemorrhage. 
To facilitate and unify the clinical diagnosis for PXE, three major diagnostic criteria 
(characteristic skin involvement, characteristic histopathological features of lesional skin, 
characteristic ocular disease) and two minor criteria ( characteristic dermatopathological 
features in nonlesional skin, family history of PXE in first-degree relatives) were defined 
and divided in five categories (1, Ila-d) at the consensuses conference in 1992. 18 
5 
The objectives of this study were to evaluate the diagnostic criteria for PXE in the context 
of precise molecular data. 
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PATIENTS AND METHODS 
Ali subjects with PXE or a positive family history of PXE were eligible for this study. 
Institutional ethic committee approved consent was obtained from ail adults, children 
when age appropriate or their parents. A detailed family and medical history was noted. 
Ali volunteers were subject to clinical examination. Dermatological and ophthalmological 
findings were photo-documented. Accurate pedigree data comprising at least three 
successive generations were compiled. For DNA extraction, blood samples were taken 
from every subject older then 16 years of age; otherwise buccal cells were collected. 
High molecular weight genomic DNA was extracted from 1ml ethylenediamine tetraacetic 
acid-anticoagulated whole blood using a commercially available, adsorption-based 
method (QlAmp, Qiagen, Valencia, CA, U.S.A), and stored at -80°C. The buccal cells 
were collected according to the protocol of Richards et al. 19 and the DNA was stored at 
4°C. Sequence and genotype analysis were done as previously reported. 2 
To correlate the extent of clinical alterations, the histopathological findings and the 
molecular genetic data, cutaneous and histological findings were graded in all subjects. 
Cutaneous clinical alterations were graded 1+ if unequivocal but sparse yellow papules 
had been noted in one or more body folds; 2+ if numerous typical, confluent yellow 
xanthoma-like lesions had been observed; and 3+ if, in addition to these changes, the 
skin was lax and redundant. Mucosal lesions were considered but not graded. 
In 23 adult subjects with typical cutaneous PXE, in four obligate heterozygotes without 
skin lesions and in three subjects with marked solar elastosis, two 5-mm skin punch-
biopsy were taken, under local anaesthesia, from a predilection site, usually in the neck 
or antecubital fossa. No biopsies were performed in children as they did not show any 
skin lesions clinically. Biopsies of unaffected skin from four volunteers who did not belong 
to one of the 10 families of the present study were used as control material. Specimens 
for light microscopy were fixed in neutral buffered formalin, dehydrated, embedded in 
paraffin, serially sectioned and stained with haematoxylin-eosin, elastin stain for elastic 
tissue and Von Kossa stain for calcium phosphates. Stained sections were code-labelled 
and examined independently by three observers without knowledge of the patient's name 
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or diagnosis. The changes consistent with PXE were graded 1+ if small, patchy areas of 
swollen, fragmented and irregularly clumped elastic fibres were seen in the mid dermis of 
sections stained by haematoxylin and eosin and elastin stains and if small amounts of 
calcium were seen in the same areas in serial sections stained by Von Kossa method. A 
3+ score was given if all the elastic fibres in a wide band throughout the mid and lower 
dermis were affected. Sections were judged to display 2+ changes if the extent of elastic 
fibres alterations lay between these two extremes. 
The diagnosis of PXE was made on the typical clinical symptoms, on dermatopathological 
findings and confirmed by molecular genetic haplotype analysis. Cases were classified 
according to established criteria for PXE on the Consensus Conference 1992. 18 Only 
individuals who showed no evidence of cutaneous and/or retinal lesions were considered 
to be clinically unaffected family members. 
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RESULTS 
We investigated 142 subjects, 79 females and 63 males, ages 3-86 years, belonging to 
10 families with PXE. Of these, 23 subjects, 15 females and eight males, ages 29-77 
years, presented the three major diagnostic criteria of PXE. In three more subjects a 
marked solar elastosis and severe macular degeneration made it impossible to exclude 
PXE clinically. These three patients, two females and one male, ages 73-79 years belong 
to the same family. They are all farmers with important sun exposure and suffer from 
'Zermatt macular dystrophy', a dominant, age-related, progressive macular dystrophy. 
In view of the variable expression and possible late onset of the disease ail 142 
individuals were included in the genetic analysis. This resulted in the identification of 25 
haplotypic h'omozygous affected individuals, 67 haplotypic heterozygous carriers and 50 
haplotypic homozygous unaffected members (Table 1). The pedigree showed a high level 
of consanguinity and a strictly horizontal pattern of disease prevalence (Fig.1). 
In 23 patients, homozygous for PXE, we observed the typical appearance (Fig.2) and 
distribution of skin lesions. The skin alterations ranged from a few yellow papules to 
confluent plaques causing redundant folds. They were regarded as slight in three 
patients, moderate in 14, and severe in six (Table 2). Eleven of the 23 patients showed 
typical cobblestone-like changes on the buccal mucosa (Fig.3). The age at onset of the 
skin lesions varied from 12 to 38 years of age in 17 patients. In six patients the skin 
lesions had never been noted before the study. The skin lesions were first noticed at a 
mean age of 17 years but a precise diagnose was made only at a mean age of 40 years 
(Table 3). Ali 67 subjects, heterozygous for PXE, and 49 of the 50 noncarriers showed no 
cutaneous or mucosal lesions of PXE. 
Independent interpretations of three histological observers regarding presence or 
absence of PXE were identical for 31 of 34 biopsy sections. The 23 cases, homozygous 
for PXE, showed the characteristic histological alterations. They were regarded as slight 
in three patients, moderate in 16, and severe in four. The correlation between the 
severity of clinical change and of histology was excellent (Table 2). In four heterozygous 
carriers for PXE and four volunteers the skin biopsy of nonlesional skin showed no 
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histological alterations. In three patients (two homozygous for PXE and one noncarrier) 
with marked solar elastosis and severe macular degeneration, the clinical and histological 
interpretation was not clear. Haematoxylin and eosin-stained sections were usually 
adequate for detection of PXE. Von Kossa staining for calcium was of additional value in 
confirming subtle lesions, while elastic tissue staining was least useful. 
Ali 23 of homozygous patients for PXE had angioid streaks and peau d'orange 
pigmentation in both eyes (Fig.4). Eight of the 23 had subretinal neomembranous 
complications at the posterior pole leading to visual impairment. The fundus lesions were 
diagnosed at a mean age of 47.8 years and initial ophthalmic complications presented in 
middle age (Table 3). In the three patients (two homozygous for PXE and one noncarrier) 
whose clinical and histological interpretation was not clear for PXE, important scarring of 
the retina made the diagnosis of angioid steaks or peau d'orange impossible. In our 
series, the ophthalmologic manifestations were responsible for more morbidity than the 
involvement of any other organ system. 
The most common findings of cardiovascular manifestation in the 23 confirmed cases of 
PXE were hypertension (> 140/90) in 11 patients (48%) at a mean age of 62.2 years, 
heart murmurs in 10 (43%) at a mean age of 49.6, coronary artery disease (CAO) in 
eight (35%) at a mean age of 59.4, abnormal pedal pulses in three (13%) at a mean age 
of 66.7, intermittent claudication in three (13%) at a mean age of 53.7 and strokes in 
three (13%) at a mean age of patients 72.7 years. These patients showed no other risk 
factor for cardiovascular diseases such as diabetes, tobacco abuse or high blood 
cholesterol levels. 
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DISCUSSION 
In this paper we exploit molecular genetic haplotype analysis to review the validity of 
clinical and histological criteria to diagnose PXE. The 10 examined families corne from 
isolates of the Swiss Valais canton, a reg ion of genetic nondisperation, offering a unique 
source for genetic analysis. In this specific region the PXE incidence is approximately 1 in 
10'000 and the heterozygote frequency is 1 in 50. 19 In general estimates, the prevalence 
PXE ranges from 1 in 70'000 to 1 in 1 million 10 • 
In our study we found 67 haplotypic heterozygous carriers, 50 haplotypic homozygous 
unaffected family members and 25 haplotypic homozygous affected individuals. They ail 
showed autosomal recessive inheritance. According to the diagnostic criteria for PXE 
defined at the consensuses conference held in 1992,18 we classified 23 of 25 homozygous 
PXE carriers, clinically as category I (three major criteria). We did not find ocular disease 
compatible with PXE in any of our haplotypic heterozygous carriers. This allowed us to 
exclude the presence of clinical type Ila (angioid streaks and two miner criteria), Ilb and 
Ile (angioid streaks and one miner criterion) PXE in our study. Category Ild (two miner 
criteria) PXE was excluded in four of 67 heterozygous carriers, as only four had biopsies 
of nonlesional skin. Further histological examinations of nonlesional skin would be needed 
to prove the absence of this category. 
We observed that the phenotypic manifestations of PXE can show considerable variability 
within families. There was no correlation seen between the severity of skin, eye or 
cardiovascular lesions within the same patient. The genetic patterns studied correlated 
with the presence or absence of disease but could not explain the different degrees of 
clinical involvement observed. This may indicate that disease expression is possibly 
influenced by environmental factors. 
The average time between the onset of skin lesions and the diagnosis was 23 years. This 
prolonged time lapse can be explained by the fact that the majority of patients were not 
concerned by their skin lesions and did not seek medical advice until their initial 
ophthalmic lesions presented in middle age (average, 48 years). 
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The histopathology of the skin is an important tool to determine the difference between 
PXE and skin lesions that superficially resemble PXE, such as solar elastosis, cutis laxa, 21 
penicillamine therapy, lesions secondary to vitamin D toxicity or renal disease. 
It is important to keep in mind that isolated angioid streaks without any other features 
do not allow a formai diagnosis of PXE. They are observed in many other diseases 22 and 
should be regarded as a sign of a possible generalized disorder. 
Cardiovascular features in PXE are well described. 17• 23 In the assessment of other organ 
systems it was surprising that gastrointestinal haemorrhage was not a major problem in 
our patients, although frequently reported in literature. 24 We observed a higher incidence 
of hypertension in patients with PXE than in the mean population. This could be explained 
by slowly progressive calcification of the elastic arterial wall 17 with graduai reduction of 
vessel lumen. 
The clinical diagnosis of PXE can be a challenge in the presence of age changes such as 
solar elastosis or in the late stages of macular degeneration where the angioid streaks 
may be obscured. Three of our subjects showed such a marked solar elastosis and an 
important scarring of the retina that we were notable to make the diagnosis of PXE 
clinically. In this situation a reliable molecular test is helpful. The genetic analysis showed 
that two of the three had PXE. Diagnosis of the disease is important, although there is no 
treatment for the basic defect. A prophylactic lifestyle, prophylactic medical monitoring, 
and genetic counselling are highly recommended. 
This report shows an excellent correlation between haplotype and typical clinical 
manifestation (cutaneous signs, histology of lesional skin and ocular involvement) in PXE. 
It confirms the validity of the three major clinical diagnostic criteria for category I PXE. 
One of the two minor criteria, which was a positive family history of PXE, was an 
important element of diagnose in our study. The other minor diagnostic criteria, which 
consists of characteristic dermatopathological features in nonlesional skin, was not of any 
major help in the diagnosis of our patients. Besides, in patients with a positive family 
history of PXE but without cutaneous or ocular manifestations, it can be difficult to justify 
a skin biopsy. 
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FIGURE LEGENDS 
Table 1 Summary of results 
Table 2 Grading of skin lesions and histological features in 23 of 25 homozygous affected 
individuals. 
Table 3 Mean age at clinical manifestation of pseudoxanthoma elasticum. 
Fig 1. Pedigree of family 1; male (square), female (circle), carrier (dots within), affected 
(solid square or circle), dead (/), study subjects (arrow), adopted (diamond with square). 
Fig 2. Thirty-one-years-old patient with pseudoxanthoma elasticum with characteristic 
yellowish papules and plaques on the neck. 
Fig 3. Cobblestone-like changes on the buccal mucosa of a 60-years-old patient with 
pseudoxanthoma elasticum. 
Fig 4. Colour fundus photograph of the left eye of a 52-year-old patient with 
pseudoxanthoma elasticum with angioid streaks and peau d'orange. 
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TABLES AND ILLUSTRATIONS 
Table 1 
Genetie analysis Nr of Major criteria Minor criteria 
subjects 
skin + histology in Ocular + Family + histology in 
signs lesional skin signs history non lesional skin 
Homozygote for 
PXE 25 23 of 25 23 of 25 23 of 25 25 of 25 Not done 
Heterozygote 
For PXE 67 O of 67 0 of 67 o of 67 67 of 67 O of 4 
Non carrier 50 1? of 50 17 of 50 1? of 50 50 of 50 Not done 
' 
Total 142 23 23 23 142 0 
PXE, Pseudoxanthoma elasticum; ?, marked solar elastosis and retinal scarring did not 
allow to exclude PXE clinically 
Table 2 
Skin lesions Histological 
features 
lntensity No. of No. of 
Subjects Subjects 
+ 3 3 
++ 14 16 
+++ 6 4 
Total 23 23 
Table 3 
Onset of skin lesions 
Eye lesions first noted 
Ophthalmologic 
complications 
Clinical diagnosis of PXE 
Fig.l 
Fig.2 
14 
Mean age 
17 years 
47.8 years 
48 years 
40.4 years 
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Fig.3 
Fig.4 
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